Shopping Cart 0
Cart Subtotal
USD 0

AC Immune SA (ACIU) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

AC Immune SA (AC Immune) is a biopharmaceutical company that develops products for treating neurodegenerative diseases. It discovers, designs and develops innovative proprietary medicines to prevent, diagnose and treat neurodegenerative diseases associated with protein misfolding. The company develops drugs based on its two proprietary technology platforms, SupraAntigen and Morphomer. These technology platforms aid in the design, discovery and development of antibodies, small molecules and vaccines. AC Immune's product pipeline includes nine therapeutic product candidates and three diagnostic product candidates. The company's lead product candidate, crenezumab is an anti-Abeta antibody being developed in Phase III in collaboration with Genentech for treating Alzheimer's disease. AC Immune is headquartered in Lausanne, Switzerland.

AC Immune SA (ACIU)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

AC Immune SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

AC Immune SA, Medical Devices Deals, 2012 to YTD 2018 9

AC Immune SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

AC Immune SA, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

AC Immune Raises USD 22 Million In Series D Financing Round 11

Partnerships 12

AC Immune Enters into Agreement with Essex Bio-Technology 12

AC Immune Enters into Partnership with Biogen 13

AC Immune Enters into Research Agreement with Janssen Pharma 14

AC Immune Enters Into Co-Development Agreement With University of Basel 15

Licensing Agreements 16

AC Immune Enters into Licensing Agreement with Janssen Pharma 16

AC Immune Enters Into License Agreement With Piramal Imaging 17

AC Immune Enters Into Licensing Agreement With Genentech For Anti-Tau Antibodies 19

Equity Offering 21

AC Immune Raises USD17.6 Million in Rights Offering of Shares 21

AC Immune Raises USD100 Million in Rights Offering of Shares 23

AC Immune Prices IPO for USD66 Million 25

AC Immune Raises USD43.5 Million in Private Placement of Series E Preferred Shares 27

AC Immune SA-Key Competitors 28

AC Immune SA-Key Employees 29

AC Immune SA-Locations And Subsidiaries 30

Head Office 30

Recent Developments 31

Financial Announcements 31

Aug 08, 2018: Ac Immune reports second quarter 2018 financial results and corporate update 31

May 02, 2018: AC Immune Reports First Quarter 2018 Financial Results and Corporate Update 33

Mar 20, 2018: AC Immune reports full-year 2017 financial results-successful first year as a public company 35

Nov 13, 2017: AC Immune Reports Third Quarter 2017 Financial Results and Corporate Update 38

Aug 09, 2017: AC Immune Reports Second Quarter 2017 Financial Results 40

May 11, 2017: AC Immune Reports First Quarter 2017 Financial Results 42

Mar 17, 2017: AC Immune Reports Full Year 2016 Financial Results and R&D Update 44

Government and Public Interest 46

Oct 03, 2017: AC Immune Awarded Continuation of 2015 Grant from The Michael J. Fox Foundation for Parkinsons Research 46

Product News 47

11/21/2017: AC Immune to Host Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimers and other Neurodegenerative Diseases 47

11/01/2018: AC Immune to Present at 2018 Society for Neurosciences Meeting 48

Aug 22, 2017: AC Immune Discovers Next-generation Antibodies Focused On Neurodegenerative Diseases 49

Appendix 50

Methodology 50

About GlobalData 50

Contact Us 50

Disclaimer 50


List Of Figure

List of Figures

AC Immune SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

AC Immune SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

AC Immune SA, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

AC Immune SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

AC Immune SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

AC Immune SA, Deals By Therapy Area, 2012 to YTD 2018 8

AC Immune SA, Medical Devices Deals, 2012 to YTD 2018 9

AC Immune SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

AC Immune Raises USD 22 Million In Series D Financing Round 11

AC Immune Enters into Agreement with Essex Bio-Technology 12

AC Immune Enters into Partnership with Biogen 13

AC Immune Enters into Research Agreement with Janssen Pharma 14

AC Immune Enters Into Co-Development Agreement With University of Basel 15

AC Immune Enters into Licensing Agreement with Janssen Pharma 16

AC Immune Enters Into License Agreement With Piramal Imaging 17

AC Immune Enters Into Licensing Agreement With Genentech For Anti-Tau Antibodies 19

AC Immune Raises USD17.6 Million in Rights Offering of Shares 21

AC Immune Raises USD100 Million in Rights Offering of Shares 23

AC Immune Prices IPO for USD66 Million 25

AC Immune Raises USD43.5 Million in Private Placement of Series E Preferred Shares 27

AC Immune SA, Key Competitors 28

AC Immune SA, Key Employees 29

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

AC Immune SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

AC Immune SA (AC Immune) is a biopharmaceutical company that develops products for treating neurodegenerative diseases. It discovers, designs and develops innovative proprietary medicines to prevent, diagnose and treat neurodegenerative diseases associated with protein misfolding. The company develops drugs based on its two proprietary technology platforms, SupraAntigen and Morphomer. These technology platforms aid in the design, discovery and development of antibodies, small molecules and vaccines. AC Immune's product pipeline includes nine therapeutic product candidates and three diagnostic product candidates. The company's lead product candidate, crenezumab is an anti-Abeta antibody being developed in Phase III in collaboration with Genentech for treating Alzheimer's disease. AC Immune is headquartered in Lausanne, Switzerland.

AC Immune SA (ACIU)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

AC Immune SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

AC Immune SA, Medical Devices Deals, 2012 to YTD 2018 9

AC Immune SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

AC Immune SA, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

AC Immune Raises USD 22 Million In Series D Financing Round 11

Partnerships 12

AC Immune Enters into Agreement with Essex Bio-Technology 12

AC Immune Enters into Partnership with Biogen 13

AC Immune Enters into Research Agreement with Janssen Pharma 14

AC Immune Enters Into Co-Development Agreement With University of Basel 15

Licensing Agreements 16

AC Immune Enters into Licensing Agreement with Janssen Pharma 16

AC Immune Enters Into License Agreement With Piramal Imaging 17

AC Immune Enters Into Licensing Agreement With Genentech For Anti-Tau Antibodies 19

Equity Offering 21

AC Immune Raises USD17.6 Million in Rights Offering of Shares 21

AC Immune Raises USD100 Million in Rights Offering of Shares 23

AC Immune Prices IPO for USD66 Million 25

AC Immune Raises USD43.5 Million in Private Placement of Series E Preferred Shares 27

AC Immune SA-Key Competitors 28

AC Immune SA-Key Employees 29

AC Immune SA-Locations And Subsidiaries 30

Head Office 30

Recent Developments 31

Financial Announcements 31

Aug 08, 2018: Ac Immune reports second quarter 2018 financial results and corporate update 31

May 02, 2018: AC Immune Reports First Quarter 2018 Financial Results and Corporate Update 33

Mar 20, 2018: AC Immune reports full-year 2017 financial results-successful first year as a public company 35

Nov 13, 2017: AC Immune Reports Third Quarter 2017 Financial Results and Corporate Update 38

Aug 09, 2017: AC Immune Reports Second Quarter 2017 Financial Results 40

May 11, 2017: AC Immune Reports First Quarter 2017 Financial Results 42

Mar 17, 2017: AC Immune Reports Full Year 2016 Financial Results and R&D Update 44

Government and Public Interest 46

Oct 03, 2017: AC Immune Awarded Continuation of 2015 Grant from The Michael J. Fox Foundation for Parkinsons Research 46

Product News 47

11/21/2017: AC Immune to Host Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimers and other Neurodegenerative Diseases 47

11/01/2018: AC Immune to Present at 2018 Society for Neurosciences Meeting 48

Aug 22, 2017: AC Immune Discovers Next-generation Antibodies Focused On Neurodegenerative Diseases 49

Appendix 50

Methodology 50

About GlobalData 50

Contact Us 50

Disclaimer 50


List Of Figure

List of Figures

AC Immune SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

AC Immune SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

AC Immune SA, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

AC Immune SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

AC Immune SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

AC Immune SA, Deals By Therapy Area, 2012 to YTD 2018 8

AC Immune SA, Medical Devices Deals, 2012 to YTD 2018 9

AC Immune SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

AC Immune Raises USD 22 Million In Series D Financing Round 11

AC Immune Enters into Agreement with Essex Bio-Technology 12

AC Immune Enters into Partnership with Biogen 13

AC Immune Enters into Research Agreement with Janssen Pharma 14

AC Immune Enters Into Co-Development Agreement With University of Basel 15

AC Immune Enters into Licensing Agreement with Janssen Pharma 16

AC Immune Enters Into License Agreement With Piramal Imaging 17

AC Immune Enters Into Licensing Agreement With Genentech For Anti-Tau Antibodies 19

AC Immune Raises USD17.6 Million in Rights Offering of Shares 21

AC Immune Raises USD100 Million in Rights Offering of Shares 23

AC Immune Prices IPO for USD66 Million 25

AC Immune Raises USD43.5 Million in Private Placement of Series E Preferred Shares 27

AC Immune SA, Key Competitors 28

AC Immune SA, Key Employees 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

AC Immune SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.